Analysts are intrested in these 5 stocks: ( ($RXRX) ), ( ($FTNT) ), ( ($MRK) ), ( ($RIVN) ) and ( ($PYPL) ). Here is a breakdown of their recent ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

And You’re Already Late” was previously published in December 2025 with the title, “ Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade.” It has since been updated to include the ...